يعرض 1 - 9 نتائج من 9 نتيجة بحث عن '"Kirsten L. Moek"', وقت الاستعلام: 1.02s تنقيح النتائج
  1. 1
  2. 2
  3. 3

    المساهمون: University of Zurich, Fehrmann, Rudolf S N, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), Targeted Gynaecologic Oncology (TARGON), Man, Biomaterials and Microbes (MBM)

    المصدر: Oral Oncology, 80, 33-39. ELSEVIER SCIENCE BV

    وصف الملف: 1-s2.0-S1368837518300885-main.pdf - application/pdf

  4. 4

    المساهمون: Guided Treatment in Optimal Selected Cancer Patients (GUTS), Damage and Repair in Cancer Development and Cancer Treatment (DARE), ​Basic and Translational Research and Imaging Methodology Development in Groningen (BRIDGE), Medical oncology, CCA - Imaging and biomarkers

    المصدر: Clinical Cancer Research, 25(12), 3517-3527. AMER ASSOC CANCER RESEARCH
    Clinical Cancer Research, 25(12), 3517-3527. American Association for Cancer Research Inc.
    Moek, K L, Waaijer, S J H, Kok, I C, Suurs, F V, Brouwers, A H, Menke-van der Houven van Oordt, C W, Wind, T T, Gietema, J A, Schröder, C P, Mahesh, S V K, Jorritsma-Smit, A, Lub-de Hooge, M N, Fehrmann, R S N, de Groot, D J A & de Vries, E G E 2019, ' 89Zr-labeled bispecific T-cell engager AMG 211 PET shows AMG 211 accumulation in CD3-rich tissues and clear, heterogeneous tumor uptake ', Clinical Cancer Research, vol. 25, no. 12, pp. 3517-3527 . https://doi.org/10.1158/1078-0432.CCR-18-2918

    وصف الملف: application/pdf

  5. 5

    المساهمون: CCA - Cancer biology and immunology, CCA - Imaging and biomarkers, CCA - Treatment and quality of life, Medical oncology

    المصدر: Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii139-viii140. Oxford University Press
    Moek, K L, Fiedler, W M, von Einem, J C, Verheul, H M, Seufferlein, T, de Groot, D J, Heinemann, V, Kebenko, M, Menke-van der Houven van Oordt, C W, Ettrich, T J, Rasmussen, E, Bogner, P, Sable, B, Stienen, S & de Vries, E G E 2018, ' Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii139-viii140 . https://doi.org/10.1093/annonc/mdy279.414

  6. 6

    المساهمون: Medical oncology, CCA - Imaging and biomarkers, CCA - Cancer Treatment and quality of life

    المصدر: Annals of oncology : official journal of the European Society for Medical Oncology, 29. Oxford University Press
    Moek, K L, Waaijer, S J H, Kok, I C, Suurs, F V, Brouwers, A, Menke-van der Houven van Oordt, C W, Wind, T T, Gietema, J A, Schroder, C P, Mahesh, S V K, Jorritsma-Smit, A, Lub-De Hooge, M N, Fehrmann, R S N, de Groot, D J & de Vries, E G E 2018, ' Zirconium-89 (89Zr)-labeled bispecific T-cell engager (BiTE®) AMG 211 PET imaging to determine AMG 211 biodistribution in patients with gastrointestinal (GI) adenocarcinomas ', Annals of oncology : official journal of the European Society for Medical Oncology, vol. 29, pp. viii139 . https://doi.org/10.1093/annonc/mdy279.413

  7. 7
  8. 8
  9. 9